Lin P.-Y.Chen H.-Y.SUNG-LIANG YUPAN-CHYR YANG2020-06-172020-06-1720170027-8874https://scholars.lib.ntu.edu.tw/handle/123456789/502829[SDGs]SDG3cd109 protein; epidermal growth factor receptor; frrs1 protein; linc00941 protein; rhov protein; tumor marker; tumor protein; unclassified drug; tumor marker; cancer adjuvant therapy; cancer chemotherapy; cancer genetics; cancer immunotherapy; cancer mortality; cancer patient; cancer radiotherapy; cancer risk; cancer size; cancer staging; cancer survival; clinical practice; Editorial; gene expression; gene mutation; genetic screening; human; long term survival; lung adenocarcinoma; molecular evolution; personalized medicine; priority journal; protein function; RNA sequence; survival rate; treatment failure; whole exome sequencing; classification; genetics; high throughput sequencing; lung tumor; pathology; procedures; Biomarkers, Tumor; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Precision Medicineeditorial10.1093/jnci/djw238281047802-s2.0-85014823280